ISIN:IT0004147952

EQS-News: Newron presents 2023 financial results and provides 2024 outlook

Retrieved on: 
Mercredi, avril 10, 2024
Psychosis, Schizophrenia, Clozapine, XETRA, Patient, CNS, Business development, Peripheral nervous system, Psychedelic literature, Safety, TRS, PANSS, EIB, Canadian International Council, Pharmaceutical industry

Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2023, and provided an outlook for 2024.

Key Points: 
  • Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2023, and provided an outlook for 2024.
  • Results from the first 100 patients to complete six months (30 weeks) of treatment with evenamide were reported in January, followed by results in February 2023 from the same 100-person cohort at the one-year (52 weeks) timepoint.
  • These data were further strengthened, post-period in January 2024, with the final results from study 015 reviewing all study participants after one year of treatment.
  • Patient enrollment has completed and results from this study are expected in April 2024.

EQS-News:  Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million 

Retrieved on: 
Mercredi, avril 10, 2024
EUR, Frankfurt Stock Exchange, XETRA, CFO, Patient, CNS, SIX Swiss Exchange, Peripheral nervous system, Security (finance)

Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million

Key Points: 
  • Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
    The issuer is solely responsible for the content of this announcement.
  • Under the agreement, the fund subscribes to an initial 750,000 newly issued shares at a subscription price of EUR 7.33 per share, which corresponds to gross proceeds of approximately EUR 5.5 million.
  • In addition, the fund has a right to subscribe to an additional up to 1,300,000 newly issued shares until no later than January 31, 2025, at a subscription price to be calculated pursuant to an agreed formula.
  • “The investment by this specialist institutional fund is a validation of our strategy to develop innovative CNS therapies,” said Roberto Galli, CFO of Newron.

EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement

Retrieved on: 
Mercredi, avril 10, 2024
EIB, Peripheral nervous system, Patient, CNS, Schizophrenia, XETRA, European Investment Bank, BofA Securities, Pharmaceutical industry

Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.

Key Points: 
  • Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.
  • The due dates for tranches four and five will stay unchanged.
  • On the amended tranches, Newron will start paying the agreed interest rates.
  • Details of the 2018 loan agreement can be found in Newron’s 2022 Annual Report which is posted on its website.

EQS-News: Newron: Zeichnungsvereinbarung über bis zu 2,05 Millionen neu ausgegebene Aktien; Erlös von bis zu EUR 15,0 Mio.

Retrieved on: 
Mercredi, avril 10, 2024
This, IS, Swiss, ACT, Under, ANY, Other, Information, Theo Shall, Off, Buy, Rechtsprechung, Prior, Registrierung, Exemtion, From, Distribution, United, States, IT, DO, Invitation, Purchase, Heins von Have, Been, Registered-Modul, U.S., AS, May, Sold, Ther, Only, AT, Person, WHO, Are, Kingdom, Investment, Falling, Promotion, Order, High, NET, Worth, That, Made, The European, Economic Motors, Area, Member, Regulierung, With, Anleger (Finanzmarkt), CA, Actual, Recherche, Plan, Collaboration, Operation, Set, Statement, Assumption, Obligation, By, SIX, Exchange, Share, Listed

EQS-News: Newron gibt Vereinbarung mit der Europäischen Investitionsbank (EIB) über die Verschiebung der Rückzahlungstermine der anstehenden Tranchen seiner Finanzierungsvereinbarung von 2018 bekannt

Retrieved on: 
Mercredi, avril 10, 2024
EIB, Tranche, Darlehen, Unternehmen, Meilenstein, SIX, XETRA, Entwicklung, Therapie, Patient, Krankheit, Nervensystem, Einigung, Bedingung, CFO, Verpflichtetsein, Rahmen, Zeitpunkt, Pipeline, Profil, Phase, Behandlung, Arzneimittel, Daten, Safinamid, Lateinamerika, Emirat, Parkinson-Krankheit, Partner, Dokument, Aussage, Weise, Art Themen, Anfang, Studie, Kollaboration, Vermarktung, Markt, ZNS, Schmerz, Ressource, Hypothese, Strategie, Stefan Zielen, Position, Kosten, Aussicht, Ausnahme, Tatsache, Natur, Risiko, Prognose, Hochrechnung, Ergebnis, Absicht, Erwartung, Grund

EQS-News: Newron präsentiert Daten der Studie 014/015 und Pläne für weitere klinische Entwicklung von Evenamide auf dem Jahreskongress 2024 der Schizophrenia International Research Society (SIRS)

Retrieved on: 
Mercredi, avril 10, 2024
Information, Studie, Ergebnis, SIX, XETRA, Unternehmen, Entwicklung, Therapie, Patient, Krankheit, Nervensystem, ZNS, Poster, Corel Presentations, Schizophrenia, International, Recherche, Society, SIRS, Daten, Details, Adjuvante Therapie, Neuroleptikum, Schizophrenie, TRS, Arzneimittel, Analyse, Behandlung, Kriterium, Anfang, Klinische Studie, Nutzen, Rahmen, Indikation, Generation, Pipeline, Glutamate, Modulation, By, AS, ADD, IS, With, Outcome, From, Trial, Treatment, Benefit, Results, Pilot, Design, Phase, Plug-in, Symptom, Iranische Diaspora

EQS-News: Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Mercredi, avril 10, 2024
SIRS, Schizophrenia, Clozapine, XETRA, Incidence, Patient, CNS, Peripheral nervous system, Safety, TRS, Schizophrenia International Research Society, Pharmaceutical industry

The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.

Key Points: 
  • The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.
  • As previously announced by Newron, the study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events.
  • Treatment with evenamide was associated with sustained, clinically significant benefit that increased throughout the one-year course of treatment.
  • Study 008A is a four-week, randomized, double-blind and placebo-controlled study assessing the efficacy, tolerability, and safety of evenamide (30 mg bid).

EQS-News: Newron berichtet herausragende Einjahres-Ergebnisse der Studie 014/15 mit Evenamide bei behandlungsresistenter Schizophrenie (TRS)

Retrieved on: 
Jeudi, janvier 4, 2024
SIX, XETRA, Unternehmen, Entwicklung, Therapie, Patient, Krankheit, Nervensystem, Adjuvante Therapie, Neuroleptikum, Management, Schizophrenia, TRS, Chief, Officer, Behandlung, Nutzen, Dose, Verbesserung, PANS, Daten, Lauf, Woche, Wirkung, Prozess, Gehirn, Professor, Psychiatrie, Medizin, Donald, Barbara, Zucker, Medicine, Hempstead, NEW, Ergebnis, Tatsache, Kriterium, Wirksamkeit, Sicherheit, Studie, Ereignis, Einwilligung, Dokument, Aussage, Weise, Art Themen, Zeitpunkt, Anfang, Kollaboration, Vermarktung, Markt, Arzneimittel, ZNS, Schmerz, Ressource, Hypothese

EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)

Retrieved on: 
Jeudi, janvier 4, 2024
Psychiatry, XETRA, ADOS, Positive, Incidence, Clinical Global Impression, CNS, Molecular medicine, PANSS, EKG, Weight gain, Longevity, Peripheral nervous system, TRS, Patient, Pharmaceutical industry

The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.

Key Points: 
  • The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.
  • In contrast to common clinical experience, no patient “relapsed” during the one-year treatment period.
  • 25% of all patients achieved “remission” (see “About remission”), never described before in TRS patients.
  • The presentation for this conference call can be downloaded as of today, January 4, 2024, at 7 am CET, on Newron’s website ( https://www.newron.com/investors/reports-and-presentation/year/2024 ).